Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes

Trial Profile

Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Glucose intolerance; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BEGAMI
  • Most Recent Events

    • 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2012 Status changed from recruiting to completed, according to presentation of results at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 30 Oct 2008 Actual start date (May 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top